Californian drugmaker BioMarin Pharmaceutical (Nasdaq: BMRN) has announced that the US Food and Drug Administration has approved a label expansion for Brineura (cerliponase alfa).
This approval broadens the approved uses of Brineura to include children of all ages with neuronal ceroid lipofuscinosis type 2 (CLN2 disease), regardless of symptoms.
Previously, Brineura was approved for symptomatic children aged three and older with late infantile CLN2 disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze